Product Description
a candidate malaria vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04271306)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Oxford
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Malaria, Falciparum
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04271306 |
VAC082 | P1 |
Terminated |
Malaria, Falciparum |
2024-02-19 |
2025-01-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04130282 |
VAC077 | P1 |
Terminated |
Malaria, Falciparum |
2020-09-22 |
2020-09-30 |
Primary Endpoints |
|
NCT06549257 |
VAC099 | P2 |
Active, not recruiting |
Malaria, Falciparum |
2026-09-01 |
2026-02-24 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/30/2021 |
PubMed |
Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans. |
|
07/14/2021 |
PubMed |
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. |